Anavex Life Sciences Corporation
AVXL
Market Cap$642.85M
Close$
$1.58
79.6% downside
Current Fair Value
79.6% downsideOvervalued by 79.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $642.85 Million |
|---|---|
| Enterprise Value | $534.90 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.52 |
| Beta | 0.82 |
| Outstanding Shares | 85,073,769 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -17.82 |
|---|---|
| PEG | 17.82 |
| Price to Sales | - |
| Price to Book Ratio | 7.78 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -9.41 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Anavex Life Sciences Corporation
CEO: Christopher Missling Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, ...